Potential Prophylactic Treatments for COVID-19

Potential Prophylactic Treatments for COVID-19

The World Health Organization declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern at the end of January 2020 and a pandemic two months later. The virus primarily spreads between humans via respiratory droplets, and is the causative agent of Coronavirus Disease 2019 (C...

Full description

Bibliographic Details
Main Authors:	Noam Ben-Zuk, Ido-David Dechtman, Itai Henn, Libby Weiss, Amichay Afriat, Esther Krasner, Yoav Gal
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Viruses
Subjects:	SARS-CoV-2 COVID-19 treatment prophylaxis pre-exposure post-exposure
Online Access:	https://www.mdpi.com/1999-4915/13/7/1292

Similar Items

Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020
by: Anne-Lise Bienvenu, et al.
Published: (2020-12-01)

Knowledge of PEP and PrEP among people living with HIV/aids in Brazil
by: Laelson Rochelle Milanês Sousa, et al.
Published: (2021-01-01)

The prophylactic effect of hydroxychloroquine on the severity of COVID-19 infection in an asymptomatic population: A randomized clinical trial
by: Arezoo Chouhdari
Published: (2024-01-01)

Clinically Evaluated COVID-19 Drugs with Therapeutic Potential for Biological Warfare Agents
by: Ido-David Dechtman, et al.
Published: (2023-06-01)

Changes in HIV post-exposure prophylaxis prescriptions before and after the introduction of HIV pre-exposure prophylaxis at a sexual health clinic in Melbourne, Australia, 2011–2021
by: Ranjit S. Samra, et al.
Published: (2024-08-01)

Factors associated with university students’ knowledge about HIV and preand post-exposure prophylaxis
by: Ana Luísa Serrano Lima, et al.
Published: (2024-08-01)

Rabies can be a disease of puppyhood
by: Monil Singhai, et al.
Published: (2022-01-01)

PrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Future
by: Deniz Gokengin, et al.
Published: (2023-01-01)

A Mathematical Model for HIV/AIDS Under Pre-Exposure and Post-Exposure Prophylaxis
by: Erick Manuel Delgado Moya, et al.
Published: (2022-10-01)

Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis
by: Raphael B. Stricker, et al.
Published: (2021-09-01)

Purified Vero Cell Rabies Vaccine (PVRV, Verorab<sup>®</sup>): A Systematic Review of Intradermal Use Between 1985 and 2019
by: Thomas Moulenat, et al.
Published: (2020-03-01)

Post-Exposure Prophylactic Vaccination against Rabies: A Systematic Review
by: Norfazilah Ahmad, et al.
Published: (2022-05-01)

Effect the pre-exposure prophylactic of hydroxychloroquine on severe COVID-19 disease: a randomized controlled trial
by: Mahnaz Valizadeh, et al.
Published: (2023-12-01)

Knowledge and Use of PEP and PrEP Among Key Populations Tested in Community Centers in Portugal
by: Daniel Simões, et al.
Published: (2021-07-01)

Vaccination for Monkeypox Virus Infection in Humans: A Review of Key Considerations
by: Kay Choong See
Published: (2022-08-01)

Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques
by: Ivana Massud, et al.
Published: (2020-08-01)

New Rabies Vaccines for Use in Humans
by: Hildegund C. J. Ertl
Published: (2019-06-01)

Rabies death in an adolescent tribal girl diagnosed postmortem, in Kerala - the precious life, preventable loss and equity concerns
by: Zinia T. Nujum, et al.
Published: (2024-05-01)

The Route of Administration of Rabies Vaccines: Comparing the Data
by: Deborah J. Briggs, et al.
Published: (2021-06-01)

T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptide-vaccination, in Syrian hamsters
by: Eszter Somogyi, et al.
Published: (2023-01-01)

Consultations for HIV post-exposure prophylaxis before and after health insurance coverage of pre-exposure prophylaxis to a university-based emergency department in Germany
by: Lennert Böhm, et al.
Published: (2023-12-01)

The South African community pharmacy sector—an untapped reservoir for delivering HIV services
by: Tsitsi Nyamuzihwa, et al.
Published: (2023-07-01)

Awareness, knowledge, and attitudes related to HIV pre-exposure prophylaxis and other prevention strategies among physicians from Brazil and Mexico: cross-sectional web-based survey
by: Hamid Vega-Ramirez, et al.
Published: (2022-04-01)

Knowledge of health students about prophylaxis pre and post exposure to HIV
by: Matheus Costa Brandão Matos, et al.

Utilization of HIV Pre-exposure Prophylaxis and Associated Factors Among Female Sex Workers in Bahir Dar City, North-West Ethiopia, Cross-sectional Study, 2022
by: Ademe B, et al.
Published: (2023-12-01)

Occupational infection to Brucella abortus B19 vaccine despite antimicrobial prophylaxis
by: Alexandre Sampaio Moura, et al.
Published: (2021-07-01)

Impact of Educational Intervention Measures on Knowledge regarding HIV/ Occupational Exposure and Post Exposure Prophylaxis among Final Year Nursing Students of a Tertiary Care Hospital in Central India
by: Shruti Jaiswal, et al.
Published: (2010-04-01)

Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience
by: Andrea Cona, et al.
Published: (2024-07-01)

Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC
by: Ludovic Jondreville, et al.
Published: (2022-11-01)

Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era
by: Alessandra Vergori, et al.
Published: (2024-07-01)

Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project
by: Stefanie J. Vaccher, et al.
Published: (2017-12-01)

Rabies vaccines: Journey from classical to modern era
by: Bushra Khan, et al.
Published: (2025-03-01)

Bridging the knowledge gap of biomedical HIV prevention tools among sub-saharan african immigrants in France. Results from an empowerment-based intervention
by: Karna Coulibaly, et al.
Published: (2023-09-01)

Associations between perceived and actual risk of HIV infection and HIV prevention services uptake among men who have sex with men in Shandong province, China: a cross-sectional study
by: Yuxi Lin, et al.
Published: (2024-06-01)

Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial
by: Madunil A. Niriella, et al.
Published: (2020-08-01)

Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India
by: Harshith B Kadnur, et al.
Published: (2022-01-01)

Transformation of Australian Community Pharmacies Into Good Clinical Practice Compliant Trial Pharmacies for HIV Pre-Exposure Prophylaxis
by: Luxi Lal, et al.
Published: (2019-11-01)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-09-01)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
by: David Totschnig, et al.
Published: (2022-10-01)

HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: Results from a prospective observational study in Germany
by: M. Uhrmacher, et al.
Published: (2022-08-01)